Cyclic heptapeptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-02-02. Numbers and descriptions here follow the published literature rather than marketing material.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Cyclic heptapeptide | Synthetic melanocortin analogue |
| Molecular formula | C50H68N14O10 | Corresponds to a mass near 1025 daltons |
| Appearance | White to off-white powder | Lyophilised solid before reconstitution |
| Solubility | Soluble in water and polar solvents | Poor solubility in nonpolar media |
| Common synonyms | Bremelanotide, PT-141 | Code name and international name used interchangeably |
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
The lactam ring that closes the peptide backbone improves resistance to exopeptidase attack, but the molecule stays susceptible to hydrolysis and oxidation once dissolved. Degradation accelerates with temperature, extreme pH, and light exposure, and repeated freeze-thaw cycles promote aggregation and material loss. Lyophilized powder held desiccated at or below minus twenty degrees Celsius is the common way to keep reference material. Reconstituted solutions are generally kept cold and used within a short window because their stability is far lower than that of the dry solid.
Handling procedures emphasize minimizing moisture uptake, since the dried solid is hygroscopic and can draw water when warmed to room temperature before a vial is opened. Laboratories record lot number, purity, counter-ion content, and residual solvent data supplied by the producer. Impurity profiles are compared run to run, and any shift in retention time or peak shape prompts re-verification against a reference standard. Certificates of analysis are treated as claims to be checked rather than accepted at face value.
Identity and purity testing for this peptide typically relies on reversed-phase high-performance liquid chromatography with ultraviolet detection, reported as area-percent purity. Mass spectrometry, usually in tandem mode, confirms molecular mass and supports quantification in biological matrices. Sequence confirmation may use peptide mapping after enzymatic digestion, while nuclear magnetic resonance and circular dichroism supply supplementary structural detail. No single technique establishes identity alone, so laboratories compare retention time, mass, and fragment pattern against a verified reference standard.
At Guanajuato, Humboldt studied the silver mines and geological formations, requiring a special mule train to transport his mineral specimens. He continued to Morelia, noting its less favorable location compared to the ancient Tarascan center at Lake Patzcuaro, and praised the Tarascan people’s craftsmanship. At the crater of Jorullo, a volcano formed in 1759, Humboldt measured volcanic temperatures and studied the rapid development of unique plant life on the lava. Locals attributed the eruption to the actions of missionaries. The journey included an ascent of Nevado de Toluca, where Humboldt studied vegetation zones and compared them to those he had observed in South America, reinforcing his interest in plant geography. The party returned to Mexico City to prepare their specimens for shipment to Europe. Humboldt’s remaining months were filled with research, teaching, and the completion of detailed maps. He delivered lectures proposing a new system for correlating rock formations, making important contributions to the field of stratigraphy. His focus on mineralogical rather than paleontological criteria distinguished his work from that of English geologist William Smith. Humboldt also advanced the understanding of volcanic activity in Mexico, observing the alignment of volcanoes as evidence of structural weaknesses in the earth’s crust. His observations supported the theory that volcanic belts were related to tectonic fissures.
=== Cancer therapy === Experimental studies indicate that macrophages can affect all therapeutic modalities, including surgery, chemotherapy, radiotherapy, immunotherapy and targeted therapy. Macrophages can influence treatment outcomes both positively and negatively. Macrophages can be protective in different ways: they can remove dead tumor cells (in a process called phagocytosis) following treatments that kill these cells; they can serve as drug depots for some anticancer drugs; they can also be activated by some therapies to promote antitumor immunity. Macrophages can also be deleterious in several ways: for example they can suppress various chemotherapies, radiotherapies and immunotherapies. Because macrophages can regulate tumor progression, therapeutic strategies to reduce the number of these cells, or to manipulate their phenotypes, are currently being tested in cancer patients. However, macrophages are also involved in antibody mediated cytotoxicity (ADCC) and this mechanism has been proposed to be important for certain cancer immunotherapy antibodies. Similarly, studies identified macrophages genetically engineered to express chimeric antigen receptors as promising therapeutic approach to lowering tumor burden.
== Cultivation == Even though it is a highly invasive and destructive plant, this species is often sold by American nurseries as the cultivar 'Hall's Prolific' (Lonicera japonica var. halliana), and in the UK as the cultivar 'Halliana'. The cultivar is also known as Hall's Japanese honeysuckle. It is an effective groundcover and has strong-smelling flowers. It can be cultivated by seed, cuttings, or layering. In addition, it will spread itself via shoots if given enough space to grow. The variety L. japonica var. repens has gained the Royal Horticultural Society's Award of Garden Merit.
Under the new instructions, domestic media organizations were told not to report the locations or number of Pakistani airstrikes. On 17 March, the General Directorate of Intelligence (GDI) warned local media outlets not to report casualties among Taliban forces from Pakistani airstrikes, saying that doing so could have serious consequences. Afghan Media Support Organization (AMSO) reported that the Taliban had imposed extensive restrictions on the media, including censorship of security-related events, and restrictions on reporting Taliban casualties. It said that journalists had been forced to publish pro-Taliban reports, including during the border clashes with Pakistan, and that their online activities were being monitored.
=== Proposed amalgamation === By early May 2026, several district and regional councils in Northland, Taranaki, the West Coast, Waikato, the Bay of Plenty, Wellington Wairarapa, Hawke's Bay and Southland Regions were discussing options to merge into unitary authorities as part of the Sixth National Government's policy of "simplifying" local government. On 5 May, the Local Government Minister Simon Watts and the RMA Reform Minister Chris Bishop issued local councils with a three-month timeframe to come up with amalgamation plans under the new "Head Start" approach. These amalgamation plans replaced the earlier proposed "combined territorial boards" and would be assessed by the newly-established Ministry for Cities, Environment, Regions and Transport (MCERT). The Government's 2026 amalgamation ultimatum received support from several local government leaders including Mayor of Nelson Nick Smith, Mayor of Southland Rob Scott, Mayor of Timaru Nigel Brown, Mayor of South Wairarapa Dame Fran Wilde, Mayor of Whangārei Ken Couper, Mayor of New Plymouth Max Brough, and Mayor of Invercargill Tom Campbell. By contrast, Mayor of Gore Ben Bell and Mayor of Rotorua Tania Tapsell expressed reservations about merger and the short time-frame. Meanwhile Mayor of Tasman Tim King preferred that the central government decide the local government model rather than delegating it to local councils.
Sources: en.wikipedia.org
== External links == Clinical trial number NCT03422653 for "A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1)" at ClinicalTrials.gov Clinical trial number NCT03636269 for "CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-2)" at ClinicalTrials.gov
=== Erectile dysfunction === Smoking is a key cause of erectile dysfunction (ED). The incidence of erectile dysfunction (difficulty achieving and maintaining a penile erection) is approximately 85 percent higher in men who smoke compared to men who do not smoke. Smoking causes impotence because it promotes arterial narrowing and damages cells lining the inside of the arteries, thus leading to reduce penile blood flow.
=== Ajinomoto === In 2004, the market for aspartame, in which Ajinomoto, the world's largest aspartame manufacturer, had a 40% share, was 14,000 metric tons (15,000 short tons; 14,000 long tons) a year, and consumption of the product was rising by 2% a year. Ajinomoto acquired its aspartame business in 2000 from Monsanto for $67 million (equivalent to $116 million in 2024). In 2007, Asda was the first British supermarket chain to remove all artificial flavorings and colors in its store brand foods. In 2008, Ajinomoto sued Asda, part of Walmart, for a malicious falsehood action concerning its aspartame product when the substance was listed as excluded from the chain's product line, along with other "nasties". In July 2009, a British court ruled in favor of Asda. In June 2010, an appeals court reversed the decision, allowing Ajinomoto to pursue a case against Asda to protect aspartame's reputation. Asda said that it would continue to use the term "no nasties" on its own-label products, but the suit was settled in 2011 with Asda choosing to remove references to aspartame from its packaging. In November 2009, Ajinomoto announced a new brand name for its aspartame sweetener – AminoSweet.
Colonel Mukaiyama – reportedly a staff officer in the 38th Army, who became a technical advisor to the Vietnamese. Credited as the leader of Japanese forces in Vietnam; killed in combat in 1946. Colonel Masanobu Tsuji – Operations Staff Officer. Major Ishii Takuo – a staff officer in the 55th Division who had commanded a squadron of its cavalry regiment. Supposedly the youngest major in the Imperial Army at the time, he led a number of volunteers to the Vietnamese cause, becoming a colonel and military advisor to General Nguyễn Sơn. He headed the Quảng Ngãi Military Academy for a while before founding the Tuy Hòa Military Academy, and was killed by a land mine in 1950. Major Kanetoshi Toshihide – served with Major Igari in the 2nd Division and followed him to join the Việt Minh; he became Chief of Staff for General Nguyễn Giác Ngộ. Major Igawa Sei – a staff officer in the 34th Independent Mixed Brigade; he joined the Viet Minh forces, and was killed in action against the French in 1946. He allegedly conceived the idea of establishing the Quảng Ngãi Military Academy. Lieutenant Igari Kazumasa – the commander of an infantry company in the 2nd Division's 29th Infantry Regiment; he became an instructor at the Quảng Ngãi Military Academy. Lieutenant Kamo Tokuji – a platoon leader under Lieutenant Igari; he also became an instructor at the Quảng Ngãi Military Academy.
Every dollar earned is just as valuable to happiness up to a $75,000 annual income, thereafter, the value of each additional dollar earns a diminishing amount of happiness. According to the latest systematic review of the economic literature on life satisfaction, one's perception of their financial circumstances fully mediates the effects of objective circumstances on one's well-being. People overestimate the influence of wealth by 100%. Professor of Economics Richard Easterlin noted that job satisfaction does not depend on salary. In other words, having extra money for luxuries does not increase happiness as much as enjoying one's job or social network. Gilbert is thus adamant, people should go to great lengths to figure out which jobs they would enjoy, and to find a way to do one of those jobs for a living (that is, provided one is also attentive to social ties). Unemployment is detrimental to individual well-being. However, that does not hold true in countries where unemployment is widespread. Psychology Today reports that the impact of unemployment is dampened in those for whom work is less central to their identity, those who receive less criticism and less negative judgments from others, those who can meet their immediate financial obligations and those who do not see their unemployment as high stress and negative. Other protective factors include the expectation of reemployment, routines that structure one's time and evaluating oneself as worthy, competent and successful.
Sources: en.wikipedia.org
PT-141 is a laboratory code for bremelanotide, a synthetic peptide that activates melanocortin receptors. It has been developed both as an injectable pharmaceutical product and as a research chemical. The two contexts differ sharply in how identity, purity, and dosing are controlled.
It is neither a steroid nor a naturally occurring human hormone. Bremelanotide is a manufactured peptide that mimics part of the melanocortin signalling system by binding receptor proteins. Its effects come from receptor activation, not from replacing a circulating hormone.
The internal lactam bridge locks the peptide into a defined shape, which raises receptor affinity and slows enzymatic breakdown. Linear versions of the same sequence are less stable and bind more weakly. Ring geometry is therefore central to how the molecule behaves in the body.
Bremelanotide binds several melanocortin receptors, and MC4R is the subtype most often cited as responsible for its behavioural effects. Activity at MC1R, MC3R and MC5R is also reported. Selectivity is therefore described as limited rather than precise.